Esteve’s Tramadol/Celecoxib: US FDA Cites No Major Concerns, But Also No Advantages

Agency’s briefing document for 15 January review of the fixed-dose product combining an opioid and nonsteroidal anti-inflammatory reflects application of opioid benefit/risk framework described in June draft guidance.

Metal frame for pouring concrete. The construction of the reinforced concrete frame of the building.
The FDA's review of Esteve's E-58425 reflects the new opioid benefit/risk framework. • Source: Shutterstock

The US Food and Drug Administration’s review of Esteve Pharmaceuticals' fixed-dose combination of tramadol and celecoxib shows how the agency intends to apply a recent draft guidance calling attention to the comparative benefits and risks of new opioid products relative to existing analgesics.

In a briefing document released ahead of a 15 January meeting of the anesthetic and analgesic drug products and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers